65,437 trials
CML · Chronic Myelogenous Leukemia · Leukemia, Myeloid Chronic
Primary: Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone — 19.0; 28.6; 0.0 Percentage of participants
Retinoschisis · X-Linked
Primary: Adverse Events (AEs) Affecting Ocular Function That Differ Clinically From Those Expected in the Normal Course of Progression of XLRS — 3; 3; 12; 6 events
Allergic Conjunctivitis
Primary: Ocular Itching — 1.176; 1.708; 2.426; 2.362 score on a scale
Liver Tumor · Hepatocellular Carcinoma
Primary: Technical Efficacy — 107 Participants
Locally Advanced Pancreatic Ductal Adenocarcinoma · Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Incidence of Grade 3 or 4 Adverse Events — 2; 8 Participants
Mild Cognitive Impairment · Adherence, Patient · Ketosis
Primary: Retention — 90.6; 76.6 percentage of participants
Superficial, Palpable, Unresectable/Metastatic Solid Tumour
Primary: Safety and Tolerability of AGI-134 Injected Intra-tumourally (IT) — 0; 0; 0; 0 Participants
Alzheimer Disease · Dementia · Brain Diseases
Primary: Change in Caregiver Mastery — 10.9; 11.5; 12.4; 12.0 score on a scale — p=0.295
Posttraumatic Stress Disorder
Primary: Posttraumatic Stress Disorder Symptoms Measured by PTSD Checklist for DSM-5 (PCL-5) — 61.48; 58.28; 39.12; 36.30 score on a scale
Atopic Dermatitis
Primary: Change in Gene Expression Typically Associated With Atopic Dermatitis in Lesional Skin Biopsies From Baseline to Week 4 — 0.212; 0.043; 0.155; 0.048 fold change
Stroke
Primary: Action Research Arm Test (ARAT) — 3.5; 0.8 score on a scale
Metastatic Uveal Melanoma
Primary: Objective Response Rate (ORR) — 7.7 percentage of participants
COVID-19 Disease · SARS Pneumonia · Pneumonia, Viral
Primary: Solicited Adverse Events — 88.0; 68.0; 88.0; 80.0 percent of participants
Hypercholesterolemia
Primary: Assessment of the Pharmacodynamic Effect of CIVI 007 — -4.54; -71.38; -76.01; -82.27 percentage change from baseline — p=<0.0001
Blood
Primary: Wong-Baker FACES Pain Rating Scale — 1.2; 2.4 score on a scale